Login to Your Account

Set for Late-Stage Transition, Array Pads Coffers with $66M

By Jennifer Boggs
Managing Editor

Friday, November 9, 2012
After highlighting abstracts for upcoming presentations at the American Society of Hematology meeting in Atlanta and the CEO's assertion that his firm was "evolving into a late-stage development company" with five programs moving toward pivotal decisions in 2013, Array BioPharma Inc. is doubling its cash position with a $65.7 million public offering.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription